Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | ECE1 | P42892 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136357 | 0.88 | CTSK (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL4075738 | 0.86 | CYP1A2 (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL15318479 | 0.85 | CA5A (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10954836 | 0.85 | CA5A (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL11702018 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL8502694 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10957418 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL11567663 | 0.84 | CTSK (0.57) | CYP1A2CTSKELANEPRTN3MME | |
| SCHEMBL11030901 | 0.84 | CTSK (0.57) | CYP1A2CTSKELANEPRTN3MME | |
| SCHEMBL11568471 | 0.84 | CTSK (0.57) | CYP1A2CTSKELANEPRTN3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6451853-B1 | Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity | DOVETAIL TECHNOLOGIES, INC | 2002-09-17 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999042099-A1 | LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | CYP1A2 4785/4885CTSK 1049/4885TPSAB1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.